Evolving Role of BTKis in CLL/SLL: Highlights from EHA 2024

Mazyar Shadman, MD, MPH, describes his clinical approach to treating patients with high-risk CLL/SLL, including those with or without del(17p) or TP53 mutations.

A blood cancer specialist discusses the latest data from the SEQUOIA Arm D trial investigating zanubrutinib plus venetoclax in treatment-naïve patients with CLL and del(17p) and/or TP53 mutations.

An expert on hematologic malignancies discusses the ongoing CAPTIVATE trial evaluating ibrutinib plus venetoclax in patients with treatment-naïve CLL/SLL.

Following recent updates from the SEQUOIA Arm D and CAPTIVATE studies, Mazyar Shadman, MD, MPH, discusses the future implications of fixed-duration therapy for patients with CLL/SLL.

Mazyar Shadman, MD, MPH, discusses the safety profile of BTK inhibitors in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

An expert on CLL/SLL provides clinical insights on approaching the treatment of patients who progress beyond initial therapy.

Mazyar Shadman, MD, MPH, shares comprehensive insights on the latest analyses of zanubrutinib compared with other BTK inhibitors in relapsed/refractory CLL/SLL.

Following EHA 2024, an expert on hematologic malignancies provides key takeaways and reviews additional data updates on treatments for CLL/SLL.

Focusing on the future of CLL/SLL treatment, Mazyar Shadman, MD, MPH, discusses promising therapies in the pipeline.